Showing results (161-170 of 245) with videos related to
Sort By:
Pageof 25
Pharmaceuticals (Basel, Switzerland)|January 23, 2016
Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2Rena G Lapidus, Brandon A Carter-Cooper, Mariola Sadowska, et al.Blood|July 24, 2010
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemiasHima Bansal, Sanjay Bansal, Manjeet Rao, et al.Acta Haematologica|August 27, 2024
Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell TransplantationGabriela Sanchez-Petitto, Olga Goloubeva, James Childress, et al.Blood|February 21, 2004
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemiaMikkael A Sekeres, Bercedis Peterson, Richard K Dodge, et al.Blood|June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyPeter Paschka, Guido Marcucci, Amy S Ruppert, et al.Blood|October 22, 2024
A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemiaYuchen Liu, Dominique R Bollino, Osman M Bah, et al.Blood|March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Sherif S Farag, Kellie J Archer, et al.Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.Pageof 25